An interventional study of Telemonitoring of self-measured blood pressure in Hypertension, sponsored by KU Leuven. Suspended at 7 sites in Belgium. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2020-03-03.
Sponsored by KU Leuven · Not applicable, Interventional, and Treatment
The proportion of hypertensive patients achieving adequate blood pressure control meeting guideline targets remains low. Of hypertensive patients, only 50% are on antihypertensive medications. Of those on blood pressure lowering drugs, only 50% have their blood pressure controlled.
The objectives of this study are:
Hypertension affects an estimated 20% to 30% of the world's adult population. Despite the availability of numerous safe and effective pharmacologic therapies, including single-pill combinations of 2-3 drugs, the percentage of patients achieving adequate blood pressure control meeting guideline targets remains low. The rule of halves still applies. Of hypertensive patients, only 50% are on antihypertensive medications. Of those on blood pressure lowering drugs, only 50% have their blood pressure controlled. Achieving target blood pressure levels in the treatment of hypertension requires that patients take their medications not only properly (adherence), but also continue to do so throughout long-term treatment (persistence). Poor medication-taking behavior is a major problem among patients with hypertension, and is one of the main causes of failure to achieve blood pressure control. Self-measurement of blood pressure at home improves adherence to treatment and the control of blood pressure. One might even hypothesize that telemonitoring of blood pressure, which allows instantaneous feedback between doctor and patient might even be more effective than usual self-measurement in improving adherence and reaching treatment tools.
Previous studies demonstrated the feasibility of telemonitoring of blood pressure. However, several issues remain unaddressed.
LAPTOHP is a randomized parallel-group study, which will address the feasibility and potential benefits of telemonitoring of blood pressure at home. Eligible patients will be recruited at seven general practices. LAPTOHP will include three stages
6,834 studies on the registry are indexed under Hypertension; 971 are open to participants now.
This study's planned enrollment of 240 is above the median of 90 across 5,095 interventional studies indexed under Hypertension.
Browse Hypertension studies →KU Leuven is the lead sponsor of 371 studies on the registry; 63 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The clinical context is suboptimal for telemonitoring of blood pressure:
In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
Other: Telemonitoring of self-measured blood pressure
In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
Time to blood pressure control
Blood pressure control will be defined as a self-measured blood pressure at home below 135 mm Hg systolic and 85 mm Hg diastolic. Blood pressure control is assumed to be present if the aforementioned levels are attained during the week preceding the last office visit of the randomized treatment visit.
Time frame: During the treatment period, there will be no fixed interval between visits, so that doctors can apply their routine care scheme. Expected average of 3 months.
Proportion of patients reaching blood pressure control on self-measurement at home and office measurement.
Blood pressure control on office measurement is a seated blood pressure below 140 mm Hg systolic and 90 mm Hg.
Time frame: During treatment period. No fixed time interval between visits. Expected average of 3 months.
The proportion of patients reaching and maintaining blood pressure control on self-measurement and office measurement at the late follow-up visit.
A self-measured home blood pressure of less than 135 mmHg systolic and less than 85 mmHg diastolic
Time frame: Three months after achieving blood pressure control
The intensity of medical treatment.
The number of antihypertensive drug classes
Time frame: During treatment period, up to 3 months.
Adverse events
Adverse events will be recorded by a self-administered questionnaire (as in previous studies conducted in general practice in Belgium).
Time frame: During treatment period, up to 3 months.
Assessment of drug adherence.
The Morisky questionnaire will be used to assess drug adherence.
Time frame: During treatment period, up to 3 months.
Assessment of quality of life
The EQ-D5 questionnaire will be used for the assessment of quality of life.
Time frame: During treatment period, up to 3 months.
Analysis of cost-effectiveness
The cost-effectiveness analysis will be conducted from the perspective of the Belgian health care system, including both the direct and indirect costs of the intervention. The costs will be balanced against the use of medical resources, including visits, medications, and use of medical resources.
Time frame: After completion of the study (expected average is 3 months).
This study is suspended, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.